994 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
PFE Pfizer, Inc. $43.01 $252.13B N/A
Article Searches
Big Ticket Mergers Are in Focus http://www.zacks.com/stock/news/430576/big-ticket-mergers-are-in-focus?cid=CS-ZC--430576 Jun 17, 2019 - Big Ticket Mergers Are in Focus
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti http://www.zacks.com/stock/news/429548/amgen-allergan-get-fda-nod-for-herceptin-biosimilar-kanjinti?cid=CS-ZC-FT-429548 Jun 14, 2019 - FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Novartis Reports Data on Cosentyx for Psoriatic Arthritis http://www.zacks.com/stock/news/428752/novartis-reports-data-on-cosentyx-for-psoriatic-arthritis?cid=CS-ZC-FT-428752 Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Top Ranked Income Stocks to Buy for June 12th http://www.zacks.com/commentary/428514/top-ranked-income-stocks-to-buy-for-june-12th?cid=CS-ZC-FT-428514 Jun 12, 2019 - Top Ranked Income Stocks to Buy for June 12th
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer http://www.zacks.com/stock/news/428338/mercks-keytruda-wins-fda-nod-for-first-line-head-neck-cancer?cid=CS-ZC-FT-428338 Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Boost Your Portfolio's Health With These 3 Big Drug Stocks http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-ZC-FT-428332 Jun 12, 2019 - The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Lilly's Emgality Gets FDA Approval for Cluster Headache http://www.zacks.com/stock/news/425463/lillys-emgality-gets-fda-approval-for-cluster-headache?cid=CS-ZC-FT-425463 Jun 06, 2019 - Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft http://www.zacks.com/stock/news/425457/zacks-market-edge-highlights-pfizer-vanguard-sp-500-etf-global-x-social-media-etf-kraneshares-china-internet-etf-and-microsoft?cid=CS-ZC-FT-425457 Jun 06, 2019 - Zacks Market Edge Highlights: Pfizer, Vanguard S&P 500 ETF, Global X Social Media ETF, Kraneshares China Internet ETF and Microsoft
5 Reasons Pfizer Sat on a Potential New Alzheimer's Drug https://www.fool.com/investing/2019/06/06/5-reasons-pfizer-sat-on-a-potential-new-alzheimers.aspx?source=iedfolrf0000001 Jun 06, 2019 - America's largest pharmaceutical company had plenty of good reasons not to pursue a potential new Alzheimer's treatment.
Blueprint Medicines to File NDA for Avapritinib With FDA http://www.zacks.com/stock/news/425083/blueprint-medicines-to-file-nda-for-avapritinib-with-fda?cid=CS-ZC-FT-425083 Jun 05, 2019 - Blueprint Medicines' (BPMC) excessive confidence in partners for revenue recognition is still a huge cause for concern.

Pages: 123456...100

Page 1>